602.4 USD
-8.5 (-1.39%)
602.4 USD
0 (0%)
Overall MEDP gets a fundamental rating of 7 out of 10. We evaluated MEDP against 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is growing strongly while it is still valued neutral. This is a good combination! These ratings would make MEDP suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- MEDP had positive earnings in the past year.
- MEDP had a positive operating cash flow in the past year.
- MEDP had positive earnings in each of the past 5 years.
- MEDP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 24.70%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- MEDP has a Return On Equity of 147.46%. This is amongst the best in the industry. MEDP outperforms 100.00% of its industry peers.
- MEDP has a Return On Invested Capital of 91.45%. This is amongst the best in the industry. MEDP outperforms 100.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 13.75%.
- The last Return On Invested Capital (91.45%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
- Looking at the Profit Margin, with a value of 18.36%, MEDP belongs to the top of the industry, outperforming 92.98% of the companies in the same industry.
- MEDP's Profit Margin has improved in the last couple of years.
- MEDP's Operating Margin of 21.50% is amongst the best of the industry. MEDP outperforms 89.47% of its industry peers.
- MEDP's Operating Margin has improved in the last couple of years.
- MEDP has a worse Gross Margin (31.11%) than 70.18% of its industry peers.
- In the last couple of years the Gross Margin of MEDP has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDP is creating value.
- The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
- Compared to 5 years ago, MEDP has less shares outstanding
- MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 8.43 indicates that MEDP is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 8.43, MEDP belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
- MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.43 |
ROIC/WACC8.26
WACC11.07%
2.3 Liquidity
- MEDP has a Current Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- MEDP has a worse Current ratio (0.57) than 94.74% of its industry peers.
- A Quick Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
- MEDP's Quick ratio of 0.57 is on the low side compared to the rest of the industry. MEDP is outperformed by 92.98% of its industry peers.
- The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
- MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.22%, which is quite impressive.
- MEDP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 33.22% yearly.
- The Revenue has grown by 13.88% in the past year. This is quite good.
- Measured over the past years, MEDP shows a quite strong growth in Revenue. The Revenue has been growing by 19.62% on average per year.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
- The Earnings Per Share is expected to grow by 12.31% on average over the next years. This is quite good.
- The Revenue is expected to grow by 12.31% on average over the next years. This is quite good.
EPS Next Y19.52%
EPS Next 2Y15.37%
EPS Next 3Y13.96%
EPS Next 5Y12.31%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.12%
Revenue Next 5Y12.31%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 42.13, MEDP can be considered very expensive at the moment.
- MEDP's Price/Earnings ratio is in line with the industry average.
- MEDP's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.94.
- The Price/Forward Earnings ratio is 35.83, which means the current valuation is very expensive for MEDP.
- MEDP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MEDP is cheaper than 63.16% of the companies in the same industry.
- MEDP is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.94, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.13 | ||
| Fwd PE | 35.83 |
4.2 Price Multiples
- MEDP's Enterprise Value to EBITDA ratio is in line with the industry average.
- MEDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MEDP is cheaper than 82.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.07 | ||
| EV/EBITDA | 31.15 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
- MEDP's earnings are expected to grow with 13.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.16
PEG (5Y)1.27
EPS Next 2Y15.37%
EPS Next 3Y13.96%
5. Dividend
5.1 Amount
- No dividends for MEDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
602.4
-8.5 (-1.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-22 2025-10-22/amc
Earnings (Next)02-09 2026-02-09/amc
Inst Owners87.1%
Inst Owner Change0.69%
Ins Owners0.44%
Ins Owner Change-7%
Market Cap16.97B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.22
Price Target553.98 (-8.04%)
Short Float %6.28%
Short Ratio5.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)1.26%
PT rev (3m)27.9%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)11.44%
EPS NY rev (1m)0.01%
EPS NY rev (3m)5.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.13 | ||
| Fwd PE | 35.83 | ||
| P/S | 7.2 | ||
| P/FCF | 25.07 | ||
| P/OCF | 23.86 | ||
| P/B | 57.79 | ||
| P/tB | N/A | ||
| EV/EBITDA | 31.15 |
EPS(TTM)14.3
EY2.37%
EPS(NY)16.81
Fwd EY2.79%
FCF(TTM)24.02
FCFY3.99%
OCF(TTM)25.25
OCFY4.19%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)2.16
PEG (5Y)1.27
Graham Number57.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 8.43 |
F-Score8
WACC11.07%
ROIC/WACC8.26
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y19.52%
EPS Next 2Y15.37%
EPS Next 3Y13.96%
EPS Next 5Y12.31%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.12%
Revenue Next 5Y12.31%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.34%
EBIT Next 3Y15.87%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
Can you provide the valuation status for MEDPACE HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
What is the profitability of MEDP stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?
The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 42.13 and the Price/Book (PB) ratio is 57.79.
How financially healthy is MEDPACE HOLDINGS INC?
The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.